People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2014 |
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2014 |
Jonathan Sheller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Sheller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Errik Anderson | 2 | 8 |
| Philip Ferneau | 2 | 6 |
| Carl Gordon | 1 | 24 |
| Michael Ross | 1 | 18 |
| Ajay Royan | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Ian Ratcliffe | 1 | 6 |
| Philip J. Ferneau | 1 | 6 |
| Claudio Nessi | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Thomas Schuetz | 1 | 4 |
| Colin Greenspon | 1 | 3 |
| Steve Tregay | 1 | 2 |
| Scott Kennedy | 1 | 2 |
| Thomas J. Schuetz | 1 | 2 |
| CARL J. GORDON | 1 | 2 |
| Warren Kett | 1 | 1 |
| Kevin Isett | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.